Fecal Microbiota Transplantation in Irritable Bowel Syndrome and a Randomized Placebo-Controlled Trial

Holster, Savanne; Brummer, Robert Jan; Repsilber, Dirk; König, Julia

doi:10.1016/s0016-5085(17)30679-0

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After successful treatment of SIBO, the inflammatory factors in the negative group improved compared with those in the same groups before treatment, and the improvement was more significant than that in the non-negative group. This result further verified the conclusion that SIBO may be part of the pathogenesis of IBS (19). In summary, SIBO plays an important role in the occurrence of IBS.…”

Section: Discussionsupporting

confidence: 85%

Correlation between small intestinal bacterial overgrowth and irritable bowel syndrome and the prognosis of treatment

Yu¹,

Li²,

Xiang³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background:The aim of the present study was to analyze the relationship between small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS) and the prognosis of treatment.Methods: A total of127 IBS patients (IBS group) were selected, and based on the results of the methane/ hydrogen breath test, they were divided into SIBO-positive group (subdivided into the antibiotic group, microecological group, and placebo group according to difference in treatment methods) and the SIBOnegative group. The incidence of SIBO and inflammatory factors in different populations were compared. Moreover, differences in the negative conversion rate of intestinal bacterial overgrowth, symptom improvement, interleukin (IL)-1β, and IL-10 levels in the antibiotic group, microecological group, and placebo group before and after treatment were compared. Results:The IL-1β level of the IBS group was higher than that of the control group, but the level of IL-10 was lower than that of the control group (P<0.05). The level of IL-1β in the SIBO-positive group was higher than that in the SIBO-negative group, while IL-10 level was lower in the SIBO-positive group compared with the SIBO-negative group (P<0.05). Symptom scores after treatment in the antibiotic group and the microecological group were lower than those in the same groups before treatment and those in the placebo group after treatment (P<0.05). After treatment, the level of IL-1β in the antibiotic group and the microecological group decreased, whereas the level of IL-10 increased (P<0.05). Furthermore, the total clinical effective rate and negative conversion rate of the antibiotic group and the microecological group were higher than those of the placebo group (P<0.05); however, the comparison of symptom scores, inflammatory factors, and total clinical effective rate before and after treatment in the placebo group was not statistically significant (P<0.05). The symptom score after treatment in the negative conversion group was lower than that in the non-negative conversion group (P<0.05).Conclusions: SIBO plays an important role in the occurrence of IBS. Antibiotics and microecological agents can be used to correct SIBO in clinical practice to improve the symptoms of IBS patients and peripheral blood inflammatory factors.

show abstract

Section: Discussionsupporting

confidence: 85%

Correlation between small intestinal bacterial overgrowth and irritable bowel syndrome and the prognosis of treatment

Yu¹,

Li²,

Xiang³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Overall, eight SATs 7 , 11 , 12 , 16–18 , 25 , 26 ( n = 90 patients in total) and all five RCTs 10 , 13 , 20 , 28 , 29 ( n = 151 patients allocated to FMT and n = 105 controls) were included. One of the RCTs was published in full after the literature review and was later included 6 , 29 . One trial reported separate IBS‐SSS for patients treated with frozen or fresh FMT; the mean value for response to both types of FMT was calculated 13 …”

Section: Resultsmentioning

confidence: 99%

“…One of the RCTs was published in full after the literature review and was later included. 6,29 One trial reported separate IBS-SSS for patients treated with frozen or fresh FMT; the mean value for response to both types of FMT was calculated. 13 The characteristics of the included SATs and RCTs are summarized in Tables 1 and 2, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Studies on the role of FMT in IBS are limited 6–20 . Based on a narrative review, several case series showed favorable results for FMT 4 .…”

Section: Introductionmentioning

confidence: 99%

“…Studies on the role of FMT in IBS are limited. [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] Based on a narrative review, several case series showed favorable results for FMT. 4 Of five randomized controlled trials (RCTs) on IBS, the majority measured the IBS Symptom Severity Scoring System (IBS-SSS) as an outcome.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Background Modulating gut microbiota is a potential treatment for irritable bowel syndrome (IBS). This meta-analysis explored whether fecal microbiota transplantation (FMT) is successful in treating IBS. Methods A systematic review was performed to find trials on FMT in IBS. Ratios and relative ratios (RR) of improvement for single-arm trials (SATs) and randomized controlled trials (RCTs) were calculated, respectively. Changes in IBS Severity Scoring System (IBS-SSS) and IBS Quality of Life (IBS-QOL) instrument compared to baseline in FMT versus placebo groups were pooled. Results In SATs, 59.5% (95% confidence interval (CI) 49.1–69.3) of IBS patients showed significant improvement. In RCTs, there were no differences between FMT and control in improvement (RR=0.93 (95% CI 0.50–1.75)) or changes in the IBS-SSS and IBS-QOL. Conclusions FMT was not effective in IBS. Variations in FMT methods and patient factors may contribute to the heterogeneous results of the trials.

show abstract